Veradermics

Veradermics, Incorporated (NYSE: MANE) is a dermatologist-founded, late clinical-stage biopharmaceutical company developing therapeutics for pattern hair loss. It has no products approved for commercial sale and generates no revenue.

Its lead and only disclosed program is VDPHL01, a proprietary, investigational, oral, non-hormonal extended-release tablet formulation of minoxidil. A gel-matrix formulation delivers steady drug release, avoiding the high peak concentrations of immediate-release oral minoxidil while extending time above the hair-growth threshold. The design aims to maximize efficacy and minimize cardiac risk.

VDPHL01 is in registration-directed development for both men and women:
- Men: positive Phase 3 Study '304' and Phase 2/3 Study '302', including 12-month data.
- Women: positive Phase 2 Study '207'; the Phase 2/3 Study '306' is fully enrolled, with data expected in 1H27.

If approved, VDPHL01 would be the only FDA-approved oral non-hormonal pattern hair loss treatment for both sexes. Its patent protection extends to at least 2043.

The company aims to build a focused portfolio of aesthetic dermatology candidates targeting high-prevalence conditions, with potential selective expansion into medical dermatology. It is investing in commercial readiness ahead of a potential launch. Cash, equivalents and marketable securities of about $798.4 million are expected to fund operations into 2030. Updated Nov 10, 2026